

Resource Summary Report

Generated by [nidm-terms](#) on Aug 10, 2026

Ultra-LEAF(TM) Purified anti-human CD19

RRID:AB_2832580

Type: Antibody

Proper Citation

BioLegend Cat# 302268, RRID:AB_2832580

Antibody Information

URL: http://antibodyregistry.org/AB_2832580

Proper Citation: BioLegend Cat# 302268, RRID:AB_2832580

Target Antigen: CD19

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC, CyTOF??, Block, IHC

Antibody Name: Ultra-LEAF(TM) Purified anti-human CD19

Description: This monoclonal targets CD19

Target Organism: human

Clone ID: Clone HIB19

Antibody ID: AB_2832580

Vendor: BioLegend

Catalog Number: 302268

Alternative Catalog Numbers: 302267

Record Creation Time: 20250819T231940+0000

Record Last Update: 20250820T050002+0000

Ratings and Alerts

No rating or validation information has been found for Ultra-LEAF(TM) Purified anti-human CD19.

No alerts have been found for Ultra-LEAF(TM) Purified anti-human CD19.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 4 mentions in open access literature.

Listed below are recent publications. The full list is available at [nidm-terms](#) .

Lu M, et al. (2026) Homeostatic maturation programs drive human cDC2s into a tolerogenic state. Immunity, 59(5), 1201.

Kong XX, et al. (2024) Circulation immune cell landscape in canonical pathogenesis of colorectal adenocarcinoma by CyTOF analysis. iScience, 27(3), 109229.

Yu S, et al. (2023) Systemic immune profiling of Omicron-infected subjects inoculated with different doses of inactivated virus vaccine. Cell, 186(21), 4615.

Zhu Y, et al. (2023) Opioid-induced fragile-like regulatory T cells contribute to withdrawal. Cell, 186(3), 591.